Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
Provided By PR Newswire
Last update: Mar 5, 2024
-- Data support ongoing development of antibody-drug conjugate (ADC) program targeting HER3-expressing cancers –
-- On-track to nominate development candidate in 2024 --
Read more at prnewswire.com
